NeuroSense Releases Q1 2024 Business Update

CAMBRIDGE, Mass., May 2, 2024 - NeuroSense Therapeutics Ltd. (Nasdaq: NRSN), an innovator in treatments for severe neurodegenerative diseases, has shared a business update highlighting significant achievements in the first quarter of 2024.

Key Developments in Q1 2024:

1. Scientific Presentation: Merit Cudkowicz, M.D., M.Sc., chair of neurology and Director of the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital, presented comprehensive data from the PARADIGM study in ALS at the American Academy of Neurology annual meeting. This presentation was part of the Emerging Sciences session, which underscores its importance.

2. Collaboration with Genetika+: NeuroSense announced a partnership with Genetika+ to utilize their precision medicine techniques aimed at enhancing neuronal plasticity measurement. This collaboration is part of NeuroSense's ongoing Phase 2 clinical trials for Alzheimer's disease.

3. Partnership with Lonza: The company also entered into a collaboration with Lonza to identify exosome-based biomarkers. This partnership aims to advance the development of PrimeC in treating ALS.

4. PARADIGM Study Analysis: Further analysis from the PARADIGM study revealed positive results in terms of quality of life and complication-free survival, alongside favorable trends in key biomarker outcomes, such as neurofilament light chain (NfL) levels.

CEO Alon Ben-Noon remarked on the productive start to 2024 for NeuroSense, highlighting the multiple collaborations that are expected to enhance the development of PrimeC for both ALS and Alzheimer's disease. He also emphasized the validation received from the scientific community at the AAN conference, where Dr. Merit Cudkowicz presented the encouraging data.

Looking ahead, NeuroSense plans to continue fostering collaborations and aims to schedule an end-of-Phase 2 meeting with the FDA. This meeting is crucial for transitioning their research into a Phase 3 clinical trial. Additional data from the PARADIGM trial is also anticipated in the coming months.

About ALS:
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that leads to complete paralysis and death typically within 2-5 years of diagnosis. In the U.S., over 5,000 new cases are diagnosed annually, with a disease burden estimated at $1 billion per year. The prevalence of ALS is projected to increase by 24% by 2040 in the U.S. and EU.

About PrimeC:
PrimeC is NeuroSense's leading drug candidate, formulated as an extended-release oral medication combining ciprofloxacin and celecoxib. This unique combination targets multiple ALS mechanisms, including motor neuron degeneration, inflammation, iron accumulation, and RNA regulation, potentially slowing disease progression. The PARADIGM Phase 2b clinical trial showed that PrimeC met safety and tolerability endpoints, with a statistically significant slowing of disease progression in the Per Protocol population. PrimeC has been granted Orphan Drug Designation by both the U.S. FDA and the European Medicines Agency.

About NeuroSense Therapeutics:
NeuroSense Therapeutics Ltd. is a clinical-stage biotech company dedicated to developing treatments for debilitating neurodegenerative diseases, including ALS, Alzheimer's disease, and Parkinson's disease. Given the complexity of these disorders, NeuroSense focuses on creating combination therapies targeting multiple pathways involved in these conditions. Their approach is supported by extensive scientific research on a wide range of related biomarkers.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!